Monitor next 10-Q for any strategic changes under new CFO Charles Carter, but the internal promotion and orderly transition suggest continuity. No immediate trading catalyst.
Price Chart
Executive Summary
Ovid Therapeutics announced the departure of CFO Jeffery Rona by mutual agreement, effective July 6, 2026, with an internal promotion of Charles Carter (SVP of Finance) to the role. The transition is orderly, with a consulting agreement to retain Rona through December 2027, and the filing explicitly states no disagreement over accounting or operations. This is a routine executive change with no material financial impact.
Key Facts
- CFO Jeffery Rona departed July 6, 2026, by mutual agreement; no disagreement with company practices
- Charles Carter, age 59, promoted from SVP of Finance to CFO, principal financial/accounting officer and secretary
- Carter receives $460,000 annual base salary, target bonus of 35% of base, 50,000 RSUs vesting over two years, and an additional $75,000 performance bonus opportunity
- Rona receives 12 months base salary, prorated 2026 bonus, 12 months COBRA, and a consulting agreement through December 2027 with continued equity vesting during the consulting period
- Rona's post-termination non-solicitation restrictions extend for one year after separation
Financial Impact
No material financial impact disclosed; CFO compensation changes are ordinary course. Carter's total cash compensation approximates $621,000 annually plus equity; Rona's separation includes 12 months salary and prorated bonus (amounts not specified).
Risk Factors
- Potential loss of institutional knowledge if Rona's consulting engagement is not fully utilized
- Risk of further executive departures if the C-suite sees instability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-047584 |
| Document: 0001628280-26-047584-index-headers.html | 0001628280-26-047584 |
| Document: 0001628280-26-047584-index.html | 0001628280-26-047584 |
| Document: 0001628280-26-047584.txt | 0001628280-26-047584 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 144 | $2.89 | awaiting T+60 | — | $2.15 (−25.43%) |
Jul 8, 2026 15w ago | 8-K | $2.73 $2.49 | ▼ −8.79% | ▼ −11.10% | $2.15 (−21.06%) |
Jun 3, 2026 20w ago | 8-K | $2.39 $2.93 | ▲ +22.59% | ▲ +20.10% | $2.15 (−9.83%) |
May 12, 2026 23w ago | Press Release | $2.87 $2.65 | ▼ −7.67% | ▼ −12.05% | $2.15 (−24.91%) |
Apr 27, 2026 26w ago | EFFECT | $2.69 $2.38 | ▼ −11.52% | ▼ −16.30% | $2.15 (−19.89%) |
Apr 21, 2026 26w ago | S-3 | $2.66 $2.44 | ▼ −8.27% | ▼ −13.05% | $2.15 (−18.98%) |
Apr 20, 2026 27w ago | 8-K | $2.89 $2.49 | ▼ −13.84% | ▼ −20.62% | $2.15 (−25.43%) |
Mar 18, 2026 31w ago | 8-K | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers